Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment (2014 - 2018)

Ironwood Pharmaceuticals has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $151.8 million for Q3 2018.

• Asset Writedowns and Impairment for Q3 2018 came in at $151.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $153.6 million (changed 0.0% YoY), and the FY2018 annual result was $151.8 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at $151.8 million for Q3 2018 at Ironwood Pharmaceuticals, up from $1.8 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $151.8 million in Q3 2018 to a low of $1.8 million in Q2 2018.
• The 4-year median for Asset Writedowns and Impairment is $9.5 million (2014), against an average of $31.5 million.
• Peak annual rise in Asset Writedowns and Impairment reached 43.82% in 2015, while the deepest fall reached 43.82% in 2015.
• Ironwood Pharmaceuticals' Asset Writedowns and Impairment stood at $11.4 million in 2014, then sank by 56.14% to $5.0 million in 2015, then jumped by 102.0% to $10.1 million in 2016, then soared by 1402.97% to $151.8 million in 2018.
• The last three Asset Writedowns and Impairment figures came in at $151.8 million (Q3 2018), $1.8 million (Q2 2018), and $10.1 million (Q4 2016), per Business Quant data.